Bala Gur-Dedeoglu
Overview
Explore the profile of Bala Gur-Dedeoglu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sakalli-Tecim E, Gur-Dedeoglu B, Guray N
Pathol Res Pract
. 2023 Aug;
249:154780.
PMID: 37633004
Breast cancer has been among the most prominent cancers with high mortality. Currently most of the offered therapeutics are toxic; hence, less toxic therapeutic intervention is required. Here, we studied...
2.
Kilic N, Islakoglu Y, Buyuk I, Gur-Dedeoglu B, Cansaran-Duman D
Anticancer Agents Med Chem
. 2018 Nov;
19(12):1463-1472.
PMID: 30417797
Objective: Breast Cancer (BC) is the most common type of cancer diagnosed in women. A common treatment strategy for BC is still not available because of its molecular heterogeneity and...
3.
Dayangac-Erden D, Gur-Dedeoglu B, Eskici F, Oztemur-Islakoglu Y, Erdem-Ozdamar S
OMICS
. 2018 Aug;
22(9):598-606.
PMID: 30106667
Spinal muscular atrophy (SMA) is one of the most common childhood onset neurodegenerative disorders in global health whereby novel biomarkers and therapeutic targets are sorely needed. SMA is an autosomal...
4.
The ability to generate senescent progeny as a mechanism underlying breast cancer cell heterogeneity
Mumcuoglu M, Bagislar S, Yuzugullu H, Alotaibi H, Senturk S, Telkoparan P, et al.
PLoS One
. 2010 Jun;
5(6):e11288.
PMID: 20585577
Background: Breast cancer is a remarkably heterogeneous disease. Luminal, basal-like, "normal-like", and ERBB2+ subgroups were identified and were shown to have different prognoses. The mechanisms underlying this heterogeneity are poorly...
5.
Gur-Dedeoglu B, Konu O, Bozkurt B, Ergul G, Seckin S, Yulug I
Oncol Res
. 2009 Jun;
17(8):353-65.
PMID: 19544972
Quantitative gene expression measurements from tumor tissue are frequently compared with matched normal and/or adjacent tumor tissue expression for diagnostic marker gene selection as well as assessment of the degree...
6.
Gur-Dedeoglu B, Konu O, Kir S, Ozturk A, Bozkurt B, Ergul G, et al.
BMC Cancer
. 2009 Jan;
8:396.
PMID: 19116033
Background: Accuracy in the diagnosis of breast cancer and classification of cancer subtypes has improved over the years with the development of well-established immunohistopathological criteria. More recently, diagnostic gene-sets at...
7.
Yulug I, Gur-Dedeoglu B
Brief Funct Genomic Proteomic
. 2008 Mar;
7(1):1-7.
PMID: 18326545
Conventional molecular and genetic methods for studying cancer are limited to the analysis of one locus at a time. A cluster of genes that are regulated together can be identified...
8.
Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya H, Gur-Dedeoglu B, Yulug I
Anticancer Res
. 2007 Jan;
26(6C):4975-7.
PMID: 17214373
Background: A T-to-G polymorphism (SNP309) at the promoter region of MDM2 has been recently reported to extend the Sp1 binding site that positively regulates the MDM2 transcription level and consequently,...